Harvard College

Beth Israel Deaconess Medical Center, Inc.

Carnegie Mellon University

Sidi A Bencherif

David J Mooney

Roger Warren Sands

Aristidis Veves

Sandeep T Koshy

Cathal J Kearney

Uyanga Tsedev

Thomas Michael Braschler

David A Edwards

Jaeyun Kim

Weiwei Aileen Li

Newell Raymond Washburn

Stephen Michael Kennedy

Liang Tso Sun

The invention provides polymer compositions for cell and drug delivery.

Injectable cryogel vaccine devices and methods of use thereof

The invention provides polymer scaffolds for cell-based tissue engineering.

Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation

The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.

Prefabricated alginate-drug bandages

Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration

The invention provides cryogels whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electrical stimulus. The cryogels have interconnected macropores which greatly enhance their ability to rapidly undergo volumetric collapse when subjected to moderate electric fields. The cryogels of the invention can be easily integrated into arrays capable of rapid configurational and chromatic optical modulations, and when loaded with drugs, are able to coordinate the delivery profile of multiple drugs. The cryogel can be prepared by polymerizing an aqueous solution of charged monomers and cross-linker monomers at a temperature below the freezing temperature of the solvent.

Porous electrolytic polymer cryogels for enhanced electrical collapsibility

The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1&#x3b2;, an anti-IL-6, an anti-TNF-&#x3b1;, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.

Inflammation-regulating compositions and methods

Growing community of inventors

Dorchester, MA, United States of America

Sidi A Bencherif